FR17C1019I2 - Compose tetracyclique - Google Patents

Compose tetracyclique

Info

Publication number: FR17C1019I2
Authority: FR; France
Prior art keywords: tetracyclic compound; tetracyclic; compound
Prior art date: 2009-06-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR17C1019C

Other languages

English (en)

French (fr)

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Chugai Pharmaceutical Co Ltd

Original Assignee

Chugai Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-06-10

Filing date

2017-06-01

Publication date

2018-04-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43308919&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR17C1019(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-06-01 Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd

2017-07-21 Publication of FR17C1019I1 publication Critical patent/FR17C1019I1/fr

2018-04-27 Application granted granted Critical

2018-04-27 Publication of FR17C1019I2 publication Critical patent/FR17C1019I2/fr

Status Active legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/76—Dibenzothiophenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Oncology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)
Furan Compounds (AREA)
Indole Compounds (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Steroid Compounds (AREA)

FR17C1019C 2009-06-10 2017-06-01 Compose tetracyclique Active FR17C1019I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2009139691		2009-06-10
PCT/JP2010/059785 WO2010143664A1 (ja)	2009-06-10	2010-06-09	４環性化合物

Publications (2)

Publication Number	Publication Date
FR17C1019I1 FR17C1019I1 (no)	2017-07-21
FR17C1019I2 true FR17C1019I2 (fr)	2018-04-27

Family

ID=43308919

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR17C1019C Active FR17C1019I2 (fr)	2009-06-10	2017-06-01	Compose tetracyclique

Country Status (40)

Country	Link
US (6)	US9126931B2 (no)
EP (4)	EP2441753B1 (no)
JP (2)	JP4588121B1 (no)
KR (1)	KR101351120B1 (no)
CN (1)	CN102459172B (no)
AR (1)	AR077025A1 (no)
AU (1)	AU2010259588B2 (no)
BR (1)	BRPI1011649B1 (no)
CA (1)	CA2764653C (no)
CL (1)	CL2011002433A1 (no)
CO (1)	CO6430460A2 (no)
CR (1)	CR20110492A (no)
CY (2)	CY1117752T1 (no)
DK (3)	DK2441753T3 (no)
EC (1)	ECSP12011573A (no)
ES (3)	ES2759510T3 (no)
FR (1)	FR17C1019I2 (no)
HK (1)	HK1165794A1 (no)
HR (3)	HRP20160605T1 (no)
HU (4)	HUE039167T2 (no)
IL (1)	IL216817A (no)
LT (3)	LT2975024T (no)
LU (1)	LUC00022I2 (no)
MA (1)	MA33418B1 (no)
MX (1)	MX2011013306A (no)
MY (1)	MY159850A (no)
NL (1)	NL300876I2 (no)
NO (2)	NO2975024T3 (no)
NZ (1)	NZ597477A (no)
PE (1)	PE20121065A1 (no)
PL (3)	PL2975024T3 (no)
PT (3)	PT2441753E (no)
RS (1)	RS58855B1 (no)
RU (2)	RU2585622C3 (no)
SG (1)	SG175707A1 (no)
SI (3)	SI2975024T1 (no)
TW (2)	TWI624457B (no)
UA (1)	UA107796C2 (no)
WO (1)	WO2010143664A1 (no)
ZA (1)	ZA201106938B (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE039167T2 (hu) *	2009-06-10	2018-12-28	Chugai Pharmaceutical Co Ltd	Tetraciklikus vegyületek
EP3698788A1 (en) *	2010-08-20	2020-08-26	Chugai Seiyaku Kabushiki Kaisha	Composition comprising tetracyclic compound
JP5006987B2 (ja) *	2010-11-22	2012-08-22	中外製薬株式会社	４環性化合物を含む医薬
EP2804604A1 (en) *	2011-10-31	2014-11-26	The Methodist Hospital Research Institute	Compound comprising a mao targeting/ seeker moiety for treating human gliomas
CA2865420C (en)	2012-03-06	2020-06-02	Cephalon, Inc.	Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
DK2902029T3 (en) *	2012-09-25	2018-10-29	Chugai Pharmaceutical Co Ltd	RET INHIBITOR
WO2014100431A1 (en)	2012-12-20	2014-06-26	Concert Pharmaceuticals, Inc.	Deuterated alk inhibitors
WO2014121654A1 (zh) *	2013-02-05	2014-08-14	山东轩竹医药科技有限公司	四并环激酶抑制剂
KR102283883B1 (ko) *	2013-04-02	2021-07-29	옥슬러 액퀴지션즈 리미티드	키나제 저해제
CN104109168B (zh) *	2013-04-20	2017-02-15	山东轩竹医药科技有限公司	四并环激酶抑制剂
CN104130241A (zh) *	2013-05-05	2014-11-05	山东轩竹医药科技有限公司	四并环激酶抑制剂
CN104177332A (zh) *	2013-05-20	2014-12-03	中国科学院上海药物研究所	酰胺基取代的吲哚并萘酮衍生物及其医药用途
CN104177342B (zh) *	2013-05-21	2018-01-05	中国科学院上海药物研究所	杂环基取代的吲哚并萘酮衍生物及其医药用途
WO2014190949A1 (zh) *	2013-06-01	2014-12-04	山东轩竹医药科技有限公司	四并环类间变性淋巴瘤激酶抑制剂
CN104230960B (zh) *	2013-06-06	2017-02-15	山东轩竹医药科技有限公司	四并环类间变性淋巴瘤激酶抑制剂
WO2014203152A1 (en)	2013-06-18	2014-12-24	Novartis Ag	Pharmaceutical combinations
CN104804016B (zh) *	2014-01-23	2017-06-20	山东轩竹医药科技有限公司	四并环类间变性淋巴瘤激酶抑制剂
KR102478887B1 (ko)	2014-04-25	2022-12-16	추가이 세이야쿠 가부시키가이샤	4환성 화합물을 고용량 함유하는 제제
KR20220042486A (ko)	2014-04-25	2022-04-05	추가이 세이야쿠 가부시키가이샤	4환성 화합물의 신규 결정
EP3157569B1 (en) *	2014-06-18	2019-07-24	F.Hoffmann-La Roche Ag	New pharmaceutical composition comprising non-ionic surfactants
TWI718102B (zh) *	2014-08-08	2021-02-11	日商中外製藥股份有限公司	４環性化合物的非晶質體
WO2016050171A1 (zh)	2014-09-29	2016-04-07	山东轩竹医药科技有限公司	多环类间变性淋巴瘤激酶抑制剂
CN105566307B (zh) *	2014-10-11	2019-04-23	中国科学院上海药物研究所	一类杂环取代的吲哚并萘酮衍生物、其制备方法、药物组合物及其用途
CN104402862B (zh)	2014-11-12	2016-10-05	苏州明锐医药科技有限公司	艾立替尼的制备方法
WO2016114375A1 (ja)	2015-01-16	2016-07-21	中外製薬株式会社	併用医薬
US9573932B2 (en) *	2015-03-02	2017-02-21	Yong Xu	Synthesis of intermediates in the preparation of ALK inhibitor
CN107428662B (zh) *	2015-03-11	2021-04-23	国际香料和香精公司	用于制备不饱和丙二酸酯的方法
CN110078741B (zh)	2015-04-24	2021-10-01	广州再极医药科技有限公司	稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
WO2017053657A1 (en)	2015-09-23	2017-03-30	Dana-Farber Cancer Institute, Inc.	Inhibitors of alk and srpk and methods of use
CN105777710B (zh) *	2016-04-05	2018-09-04	湖南欧亚药业有限公司	一种艾乐替尼的合成方法
CN106946650B (zh) *	2017-03-01	2021-06-08	南京远淑医药科技有限公司	一种盐酸阿雷替尼中间体的合成方法
CN107033125B (zh) *	2017-04-21	2019-09-20	湖南博奥德药业有限公司	一种艾乐替尼的制备方法
CN106928184B (zh) *	2017-04-21	2019-09-20	湖南博奥德药业有限公司	一种艾乐替尼的制备方法
CN106928125A (zh) *	2017-04-21	2017-07-07	湖南博奥德生物医药技术开发有限公司	一种艾乐替尼中间体的制备方法
CN107033124B (zh) *	2017-04-21	2019-09-20	湖南博奥德药业有限公司	一种艾乐替尼的制备方法
CN106995433A (zh) *	2017-04-21	2017-08-01	湖南博奥德生物医药技术开发有限公司	一种艾乐替尼的制备方法
CN106928185B (zh) *	2017-04-21	2019-09-20	湖南博奥德药业有限公司	一种艾乐替尼的制备方法
CN107129488A (zh) *	2017-04-21	2017-09-05	湖南博奥德生物医药技术开发有限公司	一种艾乐替尼的制备方法
CN106892860B (zh) *	2017-04-21	2019-08-02	湖南博奥德药业有限公司	一种艾乐替尼中间体的制备方法
CN110621669A (zh)	2017-05-04	2019-12-27	巴斯夫欧洲公司	防除植物病原性真菌的取代5-卤代烷基-5-羟基异噁唑类
WO2019008520A1 (en)	2017-07-05	2019-01-10	Fresenius Kabi Oncology Limited	PROCESS FOR THE PREPARATION OF ALECTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
JP7054134B2 (ja) *	2017-12-07	2022-04-13	国立大学法人京都大学	ベンゾ［ｂ］カルバゾール化合物及びそれを用いたイメージング
JP2021506820A (ja) *	2017-12-13	2021-02-22	上海科技大学ＳｈａｎｇｈａｉＴｅｃｈＵｎｉｖｅｒｓｉｔｙ	Ａｌｋタンパク質分解剤及びそれらの癌療法における使用
CN108178743A (zh) *	2018-02-08	2018-06-19	安庆奇创药业有限公司	一种艾乐替尼关键中间体的制备方法
KR102548191B1 (ko) *	2018-04-09	2023-06-28	상하이테크 유니버시티	표적 단백질 분해 화합물, 이의 항종양 응용, 이의 중간체 및 중간체의 응용
WO2019211868A1 (en) *	2018-04-30	2019-11-07	Msn Laboratories Private Limited, R&D Center	Improved process for the preparation of 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl) piperidin-1-yl]-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile hydrochloride
CA3104995A1 (en)	2018-06-29	2020-01-02	Chugai Seiyaku Kabushiki Kaisha	Pharmaceutical composition comprising poorly soluble basic agent
EP3848361A4 (en) *	2018-09-04	2022-06-15	Chugai Seiyaku Kabushiki Kaisha	TETRACYCLIC COMPOUND PRODUCTION PROCESS
CA3109686A1 (en) *	2018-09-27	2020-04-02	Dana-Farber Cancer Institute, Inc.	Degraders that target alk and therapeutic uses thereof
CN109438218B (zh) *	2018-10-23	2021-04-09	成都艾必克医药科技有限公司	一种盐酸艾乐替尼中间体2-(4-乙基-3-碘苯基)-2-甲基丙酸的合成方法
CN109384664B (zh) *	2018-11-20	2021-04-13	成都正善达生物医药科技有限公司	一种艾乐替尼中间体的制备方法
EP3556754A1 (en) *	2018-12-07	2019-10-23	Fresenius Kabi iPSUM S.r.l.	Process for the preparation of alectinib
CN111349012B (zh) *	2018-12-21	2023-01-10	上海复星星泰医药科技有限公司	一种卤代芳烃类化合物的制备方法及其中间体
JPWO2020130125A1 (ja)	2018-12-21	2021-11-04	第一三共株式会社	抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
AU2020242287A1 (en)	2019-03-21	2021-09-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110590739A (zh) *	2019-09-20	2019-12-20	中国药科大学	一种艾乐替尼的制备方法
CN114761006A (zh)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
TW202245785A (zh)	2021-01-29	2022-12-01	日商中外製藥股份有限公司	兒童癌症治療用之醫藥組成物
EP4320153A1 (en)	2021-04-09	2024-02-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of anaplastic large cell lymphoma
CN115340523B (zh) *	2021-05-12	2023-12-15	盛世泰科生物医药技术(苏州)股份有限公司	一种具有alk抑制活性的化合物及其制备方法和用途
WO2023074785A1 (ja)	2021-10-28	2023-05-04	中外製薬株式会社	シロップ剤
WO2023161233A1 (en)	2022-02-22	2023-08-31	Synthon B.V.	Solid forms of alectinib and alectinib salts
CN115677659B (zh) *	2022-10-11	2024-03-22	枣庄市润安制药新材料有限公司	一种阿雷替尼的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0892090A (ja) *	1994-07-26	1996-04-09	Tanabe Seiyaku Co Ltd	医薬組成物
DK0695755T3 (da) *	1994-08-04	1999-06-28	Hoffmann La Roche	Pyrrolocarbazoler
JPH08291285A (ja) *	1995-04-21	1996-11-05	Fuji Photo Film Co Ltd	感光性組成物及びそれを用いた要素
BR9709301A (pt)	1996-05-01	1999-08-10	Univ Mississipi	Inibidores da proteína quinase c halo-substituídos
JP2002544275A (ja) *	1999-05-14	2002-12-24	ジ・オーストラリアン・ナショナル・ユニバーシティー	化合物および治療方法
US7217709B2 (en) *	2003-02-28	2007-05-15	Inotek Pharmaceuticals Corporation	Tetracyclic benzamide derivatives and methods of use thereof
DK1454992T3 (da) *	2003-03-07	2006-10-02	Ist Naz Stud Cura Dei Tumori	Anaplastisk lymfomakinaseassay, reagenser og sammensætninger deraf
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
AU2004259012C1 (en)	2003-07-23	2012-08-02	Exelixis, Inc.	Anaplastic lymphoma kinase modulators and methods of use
US7378414B2 (en) *	2003-08-25	2008-05-27	Abbott Laboratories	Anti-infective agents
EP1687305B1 (en)	2003-11-21	2008-07-09	Novartis AG	1h-imidazoquinoline derivatives as protein kinase inhibitors
AU2004296905A1 (en)	2003-12-12	2005-06-23	Merck Frosst Canada Ltd	Cathepsin cysteine protease inhibitors
JP4927704B2 (ja)	2004-03-19	2012-05-09	シュペーデル・エクスペリメンタ・アーゲー	有機化合物
WO2005097765A1 (en)	2004-03-31	2005-10-20	Exelixis, Inc.	Anaplastic lymphoma kinase modulators and methods of use
WO2006021884A2 (en) *	2004-08-26	2006-03-02	Pfizer Inc.	Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
GB0517329D0 (en)	2005-08-25	2005-10-05	Merck Sharp & Dohme	Stimulation of neurogenesis
US20080292608A1 (en) *	2005-11-07	2008-11-27	Irm Llc	Compounds and Compositions as Ppar Modulators
US7601716B2 (en)	2006-05-01	2009-10-13	Cephalon, Inc.	Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en)	2006-08-14	2011-11-22	Chembridge Corporation	Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
ES2633318T3 (es)	2006-10-23	2017-09-20	Cephalon, Inc.	Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met
JP2010524953A (ja)	2007-04-17	2010-07-22	ブリストル−マイヤーズスクイブカンパニー	縮合ヘテロ環１１−β−ヒドロキシステロイドデヒドロゲナーゼＩ型阻害剤
TWI389893B (zh)	2007-07-06	2013-03-21	Astellas Pharma Inc	二（芳胺基）芳基化合物
CA2693901C (en)	2007-07-20	2015-12-29	Nerviano Medical Sciences S.R.L.	Substituted indazole derivatives active as kinase inhibitors
CA2932121A1 (en) *	2007-11-30	2009-06-11	Newlink Genetics Corporation	Ido inhibitors
AU2010244218B2 (en)	2009-05-07	2012-07-19	Astrazeneca Ab	Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
US8609097B2 (en)	2009-06-10	2013-12-17	Hoffmann-La Roche Inc.	Use of an anti-Tau pS422 antibody for the treatment of brain diseases
HUE039167T2 (hu) *	2009-06-10	2018-12-28	Chugai Pharmaceutical Co Ltd	Tetraciklikus vegyületek
GB0910046D0 (en)	2009-06-10	2009-07-22	Glaxosmithkline Biolog Sa	Novel compositions
EP3698788A1 (en) *	2010-08-20	2020-08-26	Chugai Seiyaku Kabushiki Kaisha	Composition comprising tetracyclic compound
DK2902029T3 (en) *	2012-09-25	2018-10-29	Chugai Pharmaceutical Co Ltd	RET INHIBITOR
KR102478887B1 (ko) *	2014-04-25	2022-12-16	추가이 세이야쿠 가부시키가이샤	4환성 화합물을 고용량 함유하는 제제
KR20220042486A (ko) *	2014-04-25	2022-04-05	추가이 세이야쿠 가부시키가이샤	4환성 화합물의 신규 결정
EP3157569B1 (en) *	2014-06-18	2019-07-24	F.Hoffmann-La Roche Ag	New pharmaceutical composition comprising non-ionic surfactants
TWI718102B (zh) *	2014-08-08	2021-02-11	日商中外製藥股份有限公司	４環性化合物的非晶質體

2010
- 2010-06-09 HU HUE15180863A patent/HUE039167T2/hu unknown
- 2010-06-09 PE PE2011002060A patent/PE20121065A1/es active IP Right Grant
- 2010-06-09 NO NO15180863A patent/NO2975024T3/no unknown
- 2010-06-09 SI SI201031676T patent/SI2975024T1/en unknown
- 2010-06-09 ES ES18158255T patent/ES2759510T3/es active Active
- 2010-06-09 DK DK10786195.7T patent/DK2441753T3/en active
- 2010-06-09 DK DK18158255T patent/DK3345903T3/da active
- 2010-06-09 NZ NZ597477A patent/NZ597477A/en unknown
- 2010-06-09 ES ES15180863T patent/ES2668775T3/es active Active
- 2010-06-09 WO PCT/JP2010/059785 patent/WO2010143664A1/ja active Application Filing
- 2010-06-09 HU HUE18158255A patent/HUE046402T2/hu unknown
- 2010-06-09 AU AU2010259588A patent/AU2010259588B2/en active Active
- 2010-06-09 TW TW105101212A patent/TWI624457B/zh active
- 2010-06-09 MY MYPI2011004483A patent/MY159850A/en unknown
- 2010-06-09 SI SI201031199A patent/SI2441753T1/sl unknown
- 2010-06-09 PT PT107861957T patent/PT2441753E/pt unknown
- 2010-06-09 PL PL15180863T patent/PL2975024T3/pl unknown
- 2010-06-09 TW TW099118688A patent/TWI531367B/zh active
- 2010-06-09 PL PL10786195.7T patent/PL2441753T3/pl unknown
- 2010-06-09 CA CA2764653A patent/CA2764653C/en active Active
- 2010-06-09 CN CN201080025574.4A patent/CN102459172B/zh active Active
- 2010-06-09 JP JP2010526082A patent/JP4588121B1/ja active Active
- 2010-06-09 MA MA34519A patent/MA33418B1/fr unknown
- 2010-06-09 AR ARP100102015A patent/AR077025A1/es active IP Right Grant
- 2010-06-09 KR KR1020117031143A patent/KR101351120B1/ko active Protection Beyond IP Right Term
- 2010-06-09 MX MX2011013306A patent/MX2011013306A/es active IP Right Grant
- 2010-06-09 RS RS20110548A patent/RS58855B1/sr unknown
- 2010-06-09 LT LTEP15180863.1T patent/LT2975024T/lt unknown
- 2010-06-09 EP EP10786195.7A patent/EP2441753B1/en active Active
- 2010-06-09 US US13/377,300 patent/US9126931B2/en active Active
- 2010-06-09 ES ES10786195.7T patent/ES2575084T3/es active Active
- 2010-06-09 EP EP19201621.0A patent/EP3613729A1/en active Pending
- 2010-06-09 PT PT181582552T patent/PT3345903T/pt unknown
- 2010-06-09 LT LT18158255T patent/LT3345903T/lt unknown
- 2010-06-09 PT PT151808631T patent/PT2975024T/pt unknown
- 2010-06-09 RU RU2011154150A patent/RU2585622C3/ru active Protection Beyond IP Right Term
- 2010-06-09 HU HUE10786195A patent/HUE028278T2/en unknown
- 2010-06-09 SI SI201031961T patent/SI3345903T1/sl unknown
- 2010-06-09 SG SG2011072295A patent/SG175707A1/en unknown
- 2010-06-09 DK DK15180863.1T patent/DK2975024T3/en active
- 2010-06-09 PL PL18158255T patent/PL3345903T3/pl unknown
- 2010-06-09 BR BRPI1011649-4A patent/BRPI1011649B1/pt active IP Right Grant
- 2010-06-09 EP EP18158255.2A patent/EP3345903B1/en active Active
- 2010-06-09 EP EP15180863.1A patent/EP2975024B1/en active Active
- 2010-06-09 RU RU2015156881A patent/RU2725140C2/ru active
- 2010-09-06 UA UAA201200237A patent/UA107796C2/ru unknown
- 2010-09-07 JP JP2010199935A patent/JP5628603B2/ja active Active
2011
- 2011-09-19 CR CR20110492A patent/CR20110492A/es unknown
- 2011-09-22 ZA ZA2011/06938A patent/ZA201106938B/en unknown
- 2011-09-30 CL CL2011002433A patent/CL2011002433A1/es unknown
- 2011-12-07 IL IL216817A patent/IL216817A/en active IP Right Grant
2012
- 2012-01-04 EC EC2012011573A patent/ECSP12011573A/es unknown
- 2012-01-06 CO CO12002119A patent/CO6430460A2/es active IP Right Grant
- 2012-06-29 HK HK12106400.7A patent/HK1165794A1/xx unknown
2015
- 2015-02-11 US US14/619,242 patent/US9440922B2/en active Active
2016
- 2016-06-02 CY CY20161100490T patent/CY1117752T1/el unknown
- 2016-06-06 HR HRP20160605TT patent/HRP20160605T1/hr unknown
- 2016-07-28 US US15/221,926 patent/US20160340308A1/en not_active Abandoned
2017
- 2017-06-01 FR FR17C1019C patent/FR17C1019I2/fr active Active
- 2017-06-02 LT LTPA2017017C patent/LTC2441753I2/lt unknown
- 2017-06-02 NL NL300876C patent/NL300876I2/nl unknown
- 2017-06-06 HU HUS1700026C patent/HUS1700026I1/hu unknown
- 2017-06-12 NO NO2017026C patent/NO2017026I2/no unknown
- 2017-06-14 LU LU00022C patent/LUC00022I2/fr unknown
- 2017-07-12 CY CY2017026C patent/CY2017026I1/el unknown
2018
- 2018-04-18 HR HRP20180615TT patent/HRP20180615T1/hr unknown
2019
- 2019-01-04 US US16/239,839 patent/US20200017442A1/en not_active Abandoned
- 2019-11-07 HR HRP20192022TT patent/HRP20192022T1/hr unknown
2020
- 2020-04-29 US US16/862,125 patent/US20220306578A1/en not_active Abandoned
2022
- 2022-07-08 US US17/860,589 patent/US20230142119A1/en active Pending

Also Published As

Publication number	Publication date
PT3345903T (pt)	2019-12-09
RU2585622C2 (ru)	2016-05-27
BRPI1011649A2 (pt)	2021-04-20
ES2668775T3 (es)	2018-05-22
IL216817A0 (en)	2012-02-29
TWI624457B (zh)	2018-05-21
IL216817A (en)	2016-05-31
CR20110492A (es)	2012-03-08
DK3345903T3 (da)	2019-11-11
LT3345903T (lt)	2019-12-10
HUS1700026I1 (hu)	2017-07-28
RS58855B1 (sr)	2019-07-31
ECSP12011573A (es)	2012-02-29
AU2010259588A1 (en)	2011-10-06
EP2441753A1 (en)	2012-04-18
MA33418B1 (fr)	2012-07-03
EP3345903B1 (en)	2019-10-09
WO2010143664A1 (ja)	2010-12-16
ZA201106938B (en)	2012-12-27
DK2975024T3 (en)	2018-04-23
CA2764653A1 (en)	2010-12-16
EP2975024A1 (en)	2016-01-20
PT2975024T (pt)	2018-05-14
CN102459172A (zh)	2012-05-16
PL2975024T3 (pl)	2018-09-28
JPWO2010143664A1 (ja)	2012-11-29
AR077025A1 (es)	2011-07-27
MX2011013306A (es)	2012-01-12
PL3345903T3 (pl)	2020-02-28
FR17C1019I1 (no)	2017-07-21
RU2015156881A3 (no)	2019-08-08
CY2017026I2 (el)	2017-11-14
PT2441753E (pt)	2016-06-16
LT2975024T (lt)	2018-06-11
KR101351120B1 (ko)	2014-01-15
KR20120034677A (ko)	2012-04-12
CL2011002433A1 (es)	2012-02-17
LUC00022I2 (no)	2017-09-08
RS20110548A1 (en)	2012-08-31
HUE046402T2 (hu)	2020-03-30
HRP20180615T1 (hr)	2018-06-01
RU2585622C3 (ru)	2021-08-02
SI2441753T1 (sl)	2016-07-29
US20220306578A1 (en)	2022-09-29
CO6430460A2 (es)	2012-04-30
JP2011016830A (ja)	2011-01-27
TW201613858A (en)	2016-04-16
SI3345903T1 (sl)	2020-02-28
NL300876I1 (nl)	2017-06-14
MY159850A (en)	2017-02-15
RU2725140C2 (ru)	2020-06-30
ES2759510T3 (es)	2020-05-11
HUE028278T2 (en)	2016-12-28
HUE039167T2 (hu)	2018-12-28
CY1117752T1 (el)	2017-05-17
RU2015156881A (ru)	2019-01-18
US20230142119A1 (en)	2023-05-11
LUC00022I1 (no)	2017-06-15
LTC2441753I2 (lt)	2019-02-25
NO2017026I1 (no)	2017-06-12
UA107796C2 (en)	2015-02-25
CN102459172B (zh)	2015-06-24
CY2017026I1 (el)	2017-11-14
AU2010259588B2 (en)	2015-05-28
EP2441753A4 (en)	2014-08-27
LTPA2017017I1 (lt)	2017-06-26
ES2575084T3 (es)	2016-06-24
BRPI1011649B1 (pt)	2021-11-30
US20150150845A1 (en)	2015-06-04
PL2441753T3 (pl)	2016-09-30
HRP20160605T1 (hr)	2016-07-01
EP2975024B1 (en)	2018-03-28
SI2975024T1 (en)	2018-05-31
EP3345903A1 (en)	2018-07-11
TWI531367B (zh)	2016-05-01
JP5628603B2 (ja)	2014-11-19
TW201103537A (en)	2011-02-01
US20160340308A1 (en)	2016-11-24
NL300876I2 (nl)	2017-07-11
US9440922B2 (en)	2016-09-13
CA2764653C (en)	2018-01-02
NO2975024T3 (no)	2018-08-25
PE20121065A1 (es)	2012-08-28
JP4588121B1 (ja)	2010-11-24
HK1165794A1 (en)	2012-10-12
DK2441753T3 (en)	2016-05-30
HRP20192022T1 (hr)	2020-02-07
NZ597477A (en)	2014-03-28
US20200017442A1 (en)	2020-01-16
EP3613729A1 (en)	2020-02-26
US9126931B2 (en)	2015-09-08
SG175707A1 (en)	2011-12-29
RU2011154150A (ru)	2013-07-20
NO2017026I2 (no)	2017-06-12
US20120083488A1 (en)	2012-04-05
EP2441753B1 (en)	2016-03-30

Publication	Publication Date	Title
FR17C1019I2 (fr)	2018-04-27	Compose tetracyclique
LTC2506716I2 (lt)	2022-06-27	Nauji tricikliniai junginiai
SMT201600008B (it)	2016-02-25	Composti di piridazinone
BR112012006859A2 (pt)	2019-09-24	compostos
DK2427449T3 (da)	2013-04-22	Vinylindazolylforbindelser
BRPI1013868A2 (pt)	2016-04-05	composto diaciletilenodiamina
DK2376490T3 (da)	2013-04-15	Imidazopyridinforbindelser
BRPI1008774A2 (pt)	2016-03-08	espiroamida substituída
BRPI1013614A2 (pt)	2019-09-24	compostos substituídos de espiro-amida
BRPI1005525A2 (pt)	2016-02-23	compostos de azaazuleno
ECSP12011999A (es)	2012-07-31	Derivados benzamida sustituidos
DK2397480T3 (da)	2013-09-02	Diazepindionderivat
UY33156A (es)	2011-07-29	Nuevos compuestos tienopirrol
DK2387580T3 (da)	2014-10-13	Deoxyactagardinderivater
BRPI0923592A2 (pt)	2016-01-26	composto
DOP2011000348A (es)	2012-01-15	Construcciones casb7439
BR112012009784A2 (pt)	2016-05-17	composto benzazepínico
BR112012004643A2 (pt)	2019-09-24	compostos antibióticos
BR112012006693A2 (pt)	2015-09-08	combinação
BR112012006968A2 (pt)	2019-09-24	combinação
BRPI1009199A2 (pt)	2016-03-08	compostos de pirazinoisoquinolina
BRPI0913805A2 (pt)	2016-11-01	composto
BRPI1014080A2 (pt)	2015-08-25	Compostos substituidos de enaminocarbolina
BRPI0924006A2 (pt)	2016-01-26	estrutura
FI20095580A (fi)	2010-11-27	Kaivo